Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.61 USD
Change Today -0.13 / -7.47%
Volume 454.3K
APRI On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

apricus biosciences inc (APRI) Snapshot

Open
$1.72
Previous Close
$1.74
Day High
$1.75
Day Low
$1.53
52 Week High
02/25/15 - $2.75
52 Week Low
12/19/14 - $0.92
Market Cap
81.2M
Average Volume 10 Days
127.7K
EPS TTM
$-0.26
Shares Outstanding
50.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for APRICUS BIOSCIENCES INC (APRI)

apricus biosciences inc (APRI) Related Bloomberg News

View More Bloomberg News

apricus biosciences inc (APRI) Related Businessweek News

No Related Businessweek News Found

apricus biosciences inc (APRI) Details

Apricus Biosciences, Inc. engages in developing and commercializing products and product candidates in the areas of urology and rheumatology in the United States, Canada, Europe, and internationally. The company’s lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. Its marketing partners for Vitaros include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Recordati Ireland Ltd. (Recordati S.p.A.), Bracco S.p.A. and Laboratoires Majorelle. The company’s products under development include second-generation Vitaros, a proprietary stabilized dosage formulation that is expected to be stored at room temperature conditions; and RayVa, which is in Phase IIa clinical trial for the treatment of Raynaud’s Phenomenon. It also plans to initiate a Phase IIb trial for fispemifene, a tissue-specific selective estrogen receptor modulator to treat secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men; and out-license Femprox, a product candidate for the treatment of female sexual interest/arousal disorder. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.

23 Employees
Last Reported Date: 03/16/15
Founded in 1987

apricus biosciences inc (APRI) Top Compensated Officers

Chief Executive Officer, Secretary and Direct...
Total Annual Compensation: $453.6K
Chief Development Officer and Senior Vice Pre...
Total Annual Compensation: $11.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $1.3K
Compensation as of Fiscal Year 2014.

apricus biosciences inc (APRI) Key Developments

Apricus Biosciences, Inc. Announces Auditor Changes

On March 18, 2015, Apricus Biosciences, Inc., at the direction of the Audit Committee of the Board of Directors of the company, dismissed PricewaterhouseCoopers LLP (PwC) as the company's independent registered public accounting firm. In connection with the company's dismissal of PwC, the company appointed BDO USA, LLP as its new independent registered public accounting firm to audit the company's consolidated financial statements for the year ending December 31, 2015. The change was the result of a competitive bidding process involving several accounting firms.

Apricus Biosciences, Inc. Reports Consolidated Earnings Results for the Fourth Quarter and Year Ended Dec. 31, 2014

Apricus Biosciences, Inc. reported consolidated earnings results for the fourth quarter and year ended Dec. 31, 2014. For the quarter, the company reported total revenue of $1,907,000 compared to $362,000 a year ago. Loss from continuing operations was $17,288,000 compared to $1,635,000 a year ago. Net loss was $17,288,000 or $0.40 per basic and diluted share compared to $1,345,000 or $0.04 per basic and diluted share a year ago. The increase in the net loss was primarily due to the in-licensing of fispemifene in the fourth quarter.  For the year, the company reported total revenue of $9,259,000 compared to $2,511,000 a year ago. Loss from continuing operations was $22,477,000 compared to $15,870,000 a year ago. Net loss was $21,786,000 or $0.55 per basic and diluted share compared to $16,938,000 or $0.49 per basic and diluted share a year ago.

Apricus Biosciences, Inc. to Report Q4, 2014 Results on Mar 16, 2015

Apricus Biosciences, Inc. announced that they will report Q4, 2014 results at 8:05 PM, GMT Standard Time on Mar 16, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
APRI:US $1.61 USD -0.13

APRI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
GlaxoSmithKline PLC 1,535 GBp +4.00
Pfizer Inc $35.27 USD -0.09
View Industry Companies
 

Industry Analysis

APRI

Industry Average

Valuation APRI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.1x
Price/Book 40.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact APRICUS BIOSCIENCES INC, please visit www.apricusbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.